Navigation Links
Foamix Receives US Patent on Novel Foam Technology
Date:8/24/2009

NESS ZIONA, Israel, August 24 /PRNewswire/ -- Foamix Ltd., a leading developer of topical foams for dermatology and gynecology, announced today that it has been awarded US Patent #7575739 pertaining to its foam technology. The patent covers unique foam compositions, suitable for the treatment of heat and chemical burns, wounds, bacterial, fungal and viral infections.

Dr. Dov Tamarkin, the Company's CEO stated, "The novelty of our foam technology platform is that it enables facile delivery of active agents to the inflicted site. Our foams are breakable - they are easily applied to the sensitive area of wounds and burns and they are absorbed readily into the treated area."

Foamix expends significant resources on protecting its intellectual property. To date, Foamix has five issued U.S. patents covering its OilGel(TM) and topical foam technology platforms. An additional 70 U.S. patent applications, protecting its proprietary foam platforms are under prosecution, covering compositions, applications, methods of use and delivery devices. The Company employs leading U.S. patent counsel (Wilmer Hale, Boston) as well as an in-house intellectual property team.

About Foamix

Headquartered in Ness Ziona, Israel, Foamix Ltd. is a leading developer of topical foams for dermatology and gynecology. Foamix's state-of-the-art foams provide controlled delivery of a variety of active ingredients. Foamix is currently collaborating with 10 pharmaceutical and cosmetic companies on 12 projects in the development of proprietary dermatological and gynecologic foam drugs. Additionally, the Company has an extensive in-house pipeline of dermatological and gynecological drugs in foam presentation.

Foamix holds 5 US patents and has 70 patents pending in the United States.

For additional information please visit http://www.foamix.co.il

Press inquiries: Sigal Maymon, Foamix Ltd, +972-8-9316233 or info@foamix.co.il


'/>"/>
SOURCE Foamix Ltd
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Ferndale and Foamix Execute License Agreement for Development of Non-Steroidal Foam for Atopic Dermatitis
2. Foamix Signs Term Sheet to Acquire License to Organo-Boron Antifungal Molecules - Will Target the $11 Billion Dollars Fungal Infection Market
3. Ferndale and Foamix Enter Development of an Innovative Foam for the Treatment of Atopic Dermatitis
4. SyntheMed Receives Russian Regulatory Approval for REPEL-CV(TM)
5. Vasogen Receives NASDAQ Notification Related to Minimum Bid Price
6. Angiotech receives approval for Quill(TM) SRS PDO, MONODERM(TM), Polypropylene and Nylon product lines for sale in Brazil
7. Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA Approval for Sanqi Tablets and Yinqiao Jiedu Tablets
8. CryoLife Receives FDA 510(k) Clearance for SynerGraft(R) Processed Human Cardiac Patch Material
9. China-Biotics, Inc. Receives High-Technology Enterprise Certification to Qualify for Preferential Income Tax Rate
10. YM BIOSCIENCES USA RECEIVES CLEARANCE FROM US TREASURY DEPARTMENT TO EXTEND CLINICAL PROGRAM FOR NIMOTUZUMAB
11. REPEL-CV(TM) Adhesion Barrier Receives Endorsement of Kids With Heart
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/12/2017)... 12, 2017   Protein Sciences Corporation , ... Flublok Influenza Vaccine ®, announced today that ... good safety results and induced strong neutralizing antibodies ... product is expected to advance into human clinical ... the Institute of Technology in Immunobiologicals of the ...
(Date:1/12/2017)... , ... January 12, 2017 ... ... rapid adoption of Limfinity® Cloud, RURO has enhanced the platform to accommodate ... groups, federated login, rapid data searching, and more. In addition to these ...
(Date:1/11/2017)... ... January 11, 2017 , ... As a ... Peru studying the pathogens that cause malaria and tuberculosis. Seeing firsthand the ravages ... discovery. , Now, as an assistant professor of biology and biotechnology at Worcester ...
(Date:1/11/2017)... Yorba Linda, Ca (PRWEB) , ... January 11, ... ... in the U.S. each year and costing healthcare systems more than $23.7 billion, ... patients while controlling costs. , Among the most common sepsis-causing pathogens are ...
Breaking Biology Technology:
(Date:12/20/2016)... and GENEVA, Dec, 20, 2016   Valencell ... sensor technology, and STMicroelectronics (NYSE: STM), a ... of electronics applications, announced today the launch of ... for biometric wearables that includes ST,s compact ... Valencell,s Benchmark™ biometric sensor system. Together, SensorTile ...
(Date:12/16/2016)... , Dec 16, 2016 Research and ... System Market - Global Forecast to 2021" report to their ... The ... to grow at a CAGR of 14.06% from 2016 to 2021. ... and is projected to reach 854.8 Million by 2021. The growth ...
(Date:12/15/2016)... , Dec. 15, 2016   WaferGen Bio-systems, Inc. ... genomics technology company, announced today that on December 13, ... Department of The Nasdaq Stock Market LLC which acknowledged ... price of WaferGen,s common stock had been at $1.00 ... has regained compliance with Listing Rule 5550(a)(2) of the ...
Breaking Biology News(10 mins):